Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > paclitaxel (Taxol)

Paclitaxel (Taxol) : Bristol-Myers Squibb : Chemotherapeutic agent

Paclitaxel (Taxol) Clinical Research
Paclitaxel (Taxol) Side Effects
Paclitaxel (Taxol) & Carboplatin
Paclitaxel (Taxol) & Cisplatin
Paclitaxel (Taxol) & Vinorelbine (Navelbine)
Paclitaxel (Taxol) for SCLC

Clinical Research

Second-line Weekly Paclitaxel in Patients with Inoperable NSCLC Who Fail Combination Chemotherapy With Cisplatin (PubMed)
Phase II study published in the August issue of Lung Cancer that found second-line treatment with single-agent paclitaxel is well-tolerated, active and associated with long survivals in inoperable NSCLC patients whose disease does not respond or recurs following standard front-line platinum-based chemotherapy. [8/04]

Single Agent Paclitaxel in the Treatment of Advanced NSCLC (The Oncologist)
by Mark A. Socinski
v.4, no.5 The Oncologist (October 1999): 408-416
Reviews the role of paclitaxel in the treatment of advanced NSCLC, including single agent paclitaxel in the first-line setting, one-hour and three-hour single agent paclitaxel, weekly paclitaxel, paclitaxel vs. best supportive care, and paclitaxel in the second-line setting. Concludes that single agent paclitaxel is highly active in advanced, metastatic NSCLC and notes that the major toxicities include neutropenia, neuropathy, and myalgia/arthralgia syndrome. [10/99]

Taxol (paclitaxel) - Recent MEDLINE Abstracts (PubMed)

Taxol (paclitaxel) - Clinical Trials (PubMed)

Side Effects

Paclitaxel (Taxol) & Carboplatin

Prolonged Taxol (Paclitaxel) Plus Carboplatin (Paraplatin) Improves Anti-Cancer Therapy (Doctor's Guide)
Reports results of a study presented at the 9th World Congress on Lung Cancer that found a novel weekly regimen of Taxol and carboplatin offers a safe and effective treatment option for patients with advanced NSCLC. Based on results of this Phase II study, a Phase III trial has begun comparing the standard regimen of Taxol plus carboplatin every three weeks to the aforementioned weekly regimen. [9/00]

Paclitaxel (Taxol) & Cisplatin

Phase I/II Study of Cisplatin Combined with Weekly Paclitaxel in Patients with Advanced NSCLC (PubMed)
Abstract of a study reported in the March 22, 2004 issue of the British Journal Of Cancer that found encouraging results in treating stage IIIB/IV NSCLC patients with paclitaxel and cisplatin. The progression-free survival, the median survival time, and the 1-year survival rate were 5.5 months, 13.7 months, and 56.9%, respectively. Concludes the regimen is tolerable and very active against advanced NSCLC and recommends a Phase III study. [3/04]

Comparison of Survival and Quality of Life in Advanced NSCLC Patients Treated with Paclitaxel Combined with Cisplatin versus Etoposide with Cisplatin (PubMed)
Summarizes study results reported in the February 2000 issue of the Journal of Clinical Oncology that showed, with regard to survival, the combination of paclitaxel-cisplatin is superior to etoposide-cisplatin in patients with stage IIIB and stage IV NSCLC. Registration necessary for free access to Medscape. [2/00]

Phase II Trial of Paclitaxel by 96-Hour Continuous Infusion in Combination with Cisplatin for Patients with Advanced NSCLC (PubMed)
Summarizes study results reported in the July 2000 issue of Clinical Cancer Research that showed prolonged continuous infusion of paclitaxel (Taxol) in combination with cisplatin does not appear to be obviously superior to shorter infusion times for patients with advanced NSCLC. [7/00]

Paclitaxel (Taxol) & Vinorelbine (Navelbine)

Non-platinum Regimen Appears Active in Advanced NSCLC (
v.9, no.12 Oncology News (December 2000)
Reports results of phase I/II studies presented at the 9th World Congress on Lung Cancer that found a regimen of paclitaxel (Taxol) and vinorelbine (Navelbine) in NSCLC appears to yield results similar to those with platinum-based regimens. Registration required for free access to [12/00]

Paclitaxel (Taxol) for SCLC



Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 01-May-2011
Karen Parles, MLS Editor